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arily conserved serine/threonine protein kinase that func-
tions as a major regulator of cellular and whole-body
energy homeostasis coordinating multiple metabolic path-
ways to adapt cellular processes to the energy status.
AMPK is a heterotrimeric complex composed of one cata-
lytic (a) and two regulatory subunits (b and c). AMPK acti-
vation requires phosphorylation on Thr172 within the
activation loop of the catalytic a-subunit by upstream
kinase, identiﬁed as the liver kinase B1 (LKB1).
(2) AMPK is activated in response to a variety of physiological
processes and pathological stresses that typically change
the cellular AMP/ATP ratio caused by increasing ATP con-
sumption or reducing ATP production. Activated AMPK
switches cells from an anabolic to a catabolic state, shut-
ting down the ATP-consuming synthetic pathways and ini-
tiating an ATP-producing pathway to restore energy
balance. In addition, adipokines, such as adiponectin and
resistin, that regulate whole-body energy balance, may
also affect hepatic AMPK activity and could contribute to
the fed-to-fasted transition from anabolism to catabolism
in the liver [1].
(3) As well as responding to metabolic stresses, AMPK is acti-
vated by various pharmacological and phytochemical
products including the antidiabetic drug metformin,
AICAR, and resveratrol. Recent evidence conﬁrms that
these compounds behave as indirect AMPK activators by
causing a mild impairment of ATP synthesis [2–4]. Intrigu-
ingly, AMPK is dispensable for the effects of metformin and
AICAR on hepatic gluconeogenesis, acting directly by
reducing energy charge through inhibition of the respira-
tory-chain complex I [2,3].
(4) AMPK controls the fate of fatty acids by reducing intracellu-
lar malonyl-CoA content which is both a critical precursor
for biosynthesis of fatty acids and a potent inhibitor ofmito-
chondrial fatty acid oxidation via the allosteric regulation of
carnitine palmitoyltransferase 1 (CPT1)which catalyzes the
entry of long-chain fatty acyl-CoA intomitochondria. AMPKJournal of Hepatology 20
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(B. Viollet).phosphorylates and inhibits acetyl-CoA carboxylase (ACC)
and increases malonyl-CoA decarboxylase (MCD) activity
resulting in lower malonyl-CoA levels and, therefore, pro-
moting mitochondrial b-oxidation while simultaneously
suppressing fatty acid synthesis. The activity of glycerol-3-
phosphate acyltransferase (GPAT), the ﬁrst committed step
in triacylglycerol synthesis, is also regulated by AMPK acti-
vation. The cholesterol biosynthesis is controlled by AMPK
through direct phosphorylation and inhibition of the rate
limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase [1].
(5) Although the action of AMPK is achieved by rapid and
direct phosphorylation of key metabolic enzymes, long-
term effects have been clearly demonstrated on the
expression of a number of gene sets. AMPK promotes the
induction of the transcriptional mitochondrial gene pro-
gram and the inhibition of lipogenesis gene expression
by direct phosphorylation of transcription factors and co-
activators [1,3,5]. Interestingly, AMPK inﬂuences the
NAD+-dependent SIRT1 deacetylase activity by modulation
of NAD+ levels following induction of fatty acid oxidation
and thus may indirectly modulate the acetylation and
activity of certain transcriptional regulators in addition
to direct phosphorylation events [6]. AMPK phosphorylates
the transcriptional coactivator peroxisome proliferator-
activated receptor-c coactivator-1a (PGC-1a), which con-
trols the expression of multiple transcription factors to
induce mitochondrial biogenesis, and results in greater
mitochondrial oxidative capacity by increasing PGC1-a
expression and activation through PGC1-a promoter auto-
regulation and SIRT1-mediated deacetylation, respectively
[6,7]. AMPK participates in the regulation of lipogenesis
gene expression by phosphorylation of the carbohydrate
response element binding protein (ChREBP), reducing its
DNA binding capacity and nuclear translocation, and
down-regulating sterol regulatory element-binding pro-
tein-1c (SREBP-1c) gene expression and stability probably
through SIRT1-dependent deacetylation [1,5]. Lastly, the
phosphorylation of CREB-regulated transcription coactiva-
tor 2 (CRTC2) by AMPK promotes CRTC2 binding to 14-3-3
proteins in the cytoplasm and prevents its translocation to
the nucleus, thereby reducing CREB-dependent expression
of the gluconeogenesis genes [1], although this effect was
recently challenged [2].
(6) AMPK activation also inhibits other ATP-consuming ana-
bolic pathways such as protein synthesis. This occurs by
multiple mechanisms including inhibition of the mTOR/
S6K1 pathway, that stimulates translational initiation,11 vol. 54 j 827–829
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through sequential phosphorylation of the TSC2 tumor
suppressor by the kinases AMPK and GSK3 as well as
AMPK-dependent phosphorylation of the critical mTOR-
binding subunit raptor [8] and activation of eEF2 kinase
which inhibits the elongation step.
(7) Under nutrient starvation, the liver initiates the process of
autophagy (lysosomal breakdown of cellular proteins and
organelles) to provide amino acids for gluconeogenesis.
Recent evidence indicates that AMPK is required for
autophagy in the hepatocyte, revealing a direct connection
between energy status and autophagy initiation [9].
(8) The mTOR/S6K1 pathway exerts a negative feedback loop
on insulin signaling promoting insulin resistance via inhib-
itory serine phosphorylation of IRS1. Pharmacologic
enhancement of AMPK activity has been shown to improve
insulin sensitivity and AMPK-induced inhibition of the
mTORC1/S6K1 pathway may alleviate hepatic insulin
resistance. Additionally, AMPK activation may also modu-
late insulin’s metabolic action by increasing fatty acid oxi-
dation, thereby reducing hepatic lipotoxicity and insulin
resistance [5,10]. Therefore, the efﬁcacy of AMPK activa-
tion to reverse many metabolic disorders has provided
the rationale for the development of new pharmacological
but also nutritional AMPK activators.Conﬂict of interest
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